Recently, several independent studies have showed the important role of gut microbiota in influencing immunotherapy response in patients with melanoma, non-small cell lung cancer, and renal cell carcinoma 7-11, which provides us a new target to influence the anti-PD-1 mAb outcomes. This evidence concerns the gene PDCD1 and melanoma.